Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)

NCT00971035 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00971035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00971035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Not Taking Inhaled Corticosteroids (MOLLY)
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
February 28, 2011
Enrollment
210 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma